$6.04
5.41% yesterday
Nasdaq, Oct 24, 10:19 pm CET
ISIN
US75629V1044
Symbol
RXRX

Recursion Pharmaceuticals Stock price

$6.04
+1.16 23.77% 1M
+0.29 5.04% 6M
-0.72 10.65% YTD
-0.32 5.03% 1Y
-4.87 44.64% 3Y
-25.26 80.70% 5Y
-25.26 80.70% 10Y
-25.26 80.70% 20Y
Nasdaq, Closing price Fri, Oct 24 2025
+0.31 5.41%
ISIN
US75629V1044
Symbol
RXRX
Industry

Key metrics

Basic
Market capitalization
$2.5b
Enterprise Value
$2.0b
Net debt
positive
Cash
$525.1m
Shares outstanding
432.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
38.6 | 34.1
EV/Sales
30.8 | 27.2
EV/FCF
negative
P/B
2.7
Financial Health
Equity Ratio
71.4%
Return on Equity
-44.8%
ROCE
-57.1%
ROIC
-90.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$64.6m | $73.1m
EBITDA
$-586.4m | $-648.4m
EBIT
$-649.7m | $-672.1m
Net Income
$-649.1m | $-707.4m
Free Cash Flow
$-393.9m
Growth (TTM | estimate)
Revenue
30.2% | 24.2%
EBITDA
-53.8% | -40.9%
EBIT
-64.3% | -40.3%
Net Income
-73.1% | -52.6%
Free Cash Flow
-15.1%
Margin (TTM | estimate)
Gross
-3.5%
EBITDA
-907.8% | -887.5%
EBIT
-1,005.8%
Net
-1,004.9% | -968.3%
Free Cash Flow
-609.8%
More
EPS
$-1.6
FCF per Share
$-0.9
Short interest
32.8%
Employees
800
Rev per Employee
$70.0k
Show more

Is Recursion Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.

Recursion Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Recursion Pharmaceuticals forecast:

7x Buy
50%
7x Hold
50%

Analyst Opinions

14 Analysts have issued a Recursion Pharmaceuticals forecast:

Buy
50%
Hold
50%

Financial data from Recursion Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
65 65
30% 30%
100%
- Direct Costs 67 67
63% 63%
103%
-2.27 -2.27
127% 127%
-4%
- Selling and Administrative Expenses 216 216
69% 69%
335%
- Research and Development Expense 420 420
61% 61%
650%
-586 -586
54% 54%
-908%
- Depreciation and Amortization 63 63
349% 349%
98%
EBIT (Operating Income) EBIT -650 -650
64% 64%
-1,006%
Net Profit -649 -649
73% 73%
-1,005%

In millions USD.

Don't miss a Thing! We will send you all news about Recursion Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Recursion Pharmaceuticals Stock News

Positive
The Motley Fool
3 days ago
Many leading companies focused on artificial intelligence (AI) have seen their shares soar as they profit from the tailwind this market is currently experiencing. Perhaps a good way to cash in on this is to invest in smaller, under-the-radar players that don't attract nearly as much attention.
Neutral
The Motley Fool
4 days ago
Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals (RXRX 15.70%), reported the sale of 100,000 shares on October 10, 2025, as disclosed in a SEC Form 4 filing. It appears that Gibson converted 120,000 shares of class B common stock to class A common stock.
Positive
The Motley Fool
6 days ago
It's tough to get excited about buying most growth stocks right now. Too many of them are just too expensive relative to the risk they bring to the table.
More Recursion Pharmaceuticals News

Company Profile

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Chistopher Gibson
Employees 800
Founded 2013
Website www.recursion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today